Home > Compound List > Product Information
Phenacemide_Molecular_structure_CAS_63-98-9)
Click picture or here to close

Phenacemide

Catalog No. DB01121 Name DrugBank
CAS Number 63-98-9 Website http://www.ualberta.ca/
M. F. C9H10N2O2 Telephone (780) 492-3111
M. W. 178.1879 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 992

SYNONYMS

IUPAC name
(2-phenylacetyl)urea
IUPAC Traditional name
phenacemide
Brand Name
Neophedan
Fenacemide
Fenacemid
Phenurone
Felurea
Acetylureum
Epheron
Epiclase
Fenacetil-Karbamide
Fenilep
Fenural
Neophenal
Phenacereum
Phenicarb
Phenutal
Carbanmide
Cetylureum
Comitiadone
Eferon
Efron
Fenacetamide
Fenised
Fenostenyl
Fenurea
Fenurone
Fenylacetylmocovina
Fenytan
Phacetur
Phenacalum
Phenacetur
Phenarone
Phenuron
Phenyrit
Phetylureum
Synonyms
PA
Phenacetylcarbamide
Phenylacetylurea
Carbamide phenylacetate
Phenacetylurea
Phenylacetyluree

DATABASE IDS

PubChem CID 4753
PubChem SID 46508400
CAS Number 63-98-9

PROPERTIES

Hydrophobicity(logP) 0.8
Solubility 10.2 g/L

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
Indication Used to control certain seizures in the treatment of epilepsy.
Pharmacology Phenacemide is a ureal anticonvulsant indicated for control of severe epilepsy, particularly mixed forms of complex partial (psychomotor or temporal lobe) seizures, refractory to other anticonvulsants. Phenacemide elevates the threshold for minimal electroshock convulsions and abolishes the tonic phase of maximal electroshock seizures. It also prevents or modifies seizures induced by pentylenetetrazol or other convulsants.
Toxicity Oral, mouse: LD50 = 987 mg/kg; Oral, rabbit: LD50 = 2500 mg/kg; Oral, rat: LD50 = 1600 mg/kg
Affected Organisms
Humans and other mammals
Biotransformation Metabolized in the liver by hepatic microsomal enzymes, where it is inactivated by p-hydroxylation.
Absorption Almost completely absorbed.
Half Life 22-25 hours.
References
Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. [Pubmed]
Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. [Pubmed]
External Links
Wikipedia

REFERENCES

  • Coker SB: The use of phenacemide for intractable partial complex epilepsy in children. Pediatr Neurol. 1986 Jul-Aug;2(4):230-2. Pubmed
  • Coker SB, Holmes EW, Egel RT: Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. Pubmed